Skip to main content

Table 4 Change in patient Ki67 and vimentin CTC profile with treatment. Chi-squared test to analyse CTC frequencies in treatment groups. Samples from the second column were taken at cycles 2–3 following initiation of treatment

From: Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

  Baseline sample before treatment (%) First sample after treatment start (%)  
Number of patients with Ki67 + ve CTC (%) 23/51 (45.1) 15/39 (38.5) p = 0.528
Number of patients with ≥5 Ki67 + ve CTC (%) 12/51 (23.5) 6/39 (15.4) p = 0.336
Number of patients with Vim + ve CTC (%) 30/93 (32.3) 19/49 (38.8) p = 0.437
Number of patients with ≥5 Vim + ve CTC (%) 10/93 (10.8) 7/49 (14.3) p = 0.558